CSF/serum quotient diagrams for IgG with hyperbolic graphs (Reibergrams) for MS patients and control groups.

<p>CSF/serum quotient diagrams for IgG with hyperbolic graphs (Reibergrams) for MS patients and control groups.</p

Cytokines and cytokine ratios measured in patients and controls.

<p>Cytokines and cytokine ratios measured in patients and controls.</p

Serum cytokine ratios of MS patients and control groups.

<p>The data are presented as box plots with whiskers, showing the median with the upper (75) and lower (25) percentiles. The uncorrected p values are shown where statistical significance was reached. The asterisk (*) denotes statistical significance retained after controlling for type I error.</p

IgG index (A), QAlb (B) and QIgG (C) values of MS patients and control groups.

<p>The data are presented as box plots with whiskers, showing the median with the upper (75) and lower (25) percentiles. The uncorrected p values are shown where statistical significance was reached. The asterisk (*) denotes statistical significance retained after controlling for type I error.</p

CSF cytokine ratios of MS patients and control groups.

<p>The data are presented as box plots with whiskers, showing the median with the upper (75) and lower (25) percentiles. The uncorrected p values are shown where statistical significance was reached. The asterisk (*) denotes statistical significance retained after controlling for type I error.</p

Overall analysis of disability progression in placebo-control randomized clinical trials of different disease modifying therapies in patients with relapsing-remitting multiple sclerosis.

<p>Overall analysis of disability progression in placebo-control randomized clinical trials of different disease modifying therapies in patients with relapsing-remitting multiple sclerosis.</p

Flow chart presenting the selection of eligible studies.

<p>Flow chart presenting the selection of eligible studies.</p

Subgroup analysis according to the route of administration (injectable vs. oral) of eligible disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis.

<p>Subgroup analysis according to the route of administration (injectable vs. oral) of eligible disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis.</p

Analysis on the annualized relapse rate reduction at 2 years reported for patients with relapsing remitting multiple sclerosis included in the randomized clinical trials of Natalizumab or Fingolimod.

<p>Analysis on the annualized relapse rate reduction at 2 years reported for patients with relapsing remitting multiple sclerosis included in the randomized clinical trials of Natalizumab or Fingolimod.</p

Significant differences among patients with relapsing-remitting multiple sclerosis treated with natalizumab and patients with relapsing-remitting multiple sclerosis treated with fingolimod in the included observational study protocols and reported methods for confounders adjustment.

<p>Significant differences among patients with relapsing-remitting multiple sclerosis treated with natalizumab and patients with relapsing-remitting multiple sclerosis treated with fingolimod in the included observational study protocols and reported methods for confounders adjustment.</p